Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tryptamine Therapeutics ( (AU:ENP) ) has issued an announcement.
Entropy Neurodynamics has disclosed a change in director Chris Ntoumenopoulos’ interests, with the allotment of 10 million director options exercisable at A$0.05 and expiring on 19 December 2030. The options, issued at no consideration and approved by shareholders at the company’s 13 November 2025 meeting, increase Ntoumenopoulos’ indirect holdings and further align his remuneration with long‑term shareholder value, underscoring the company’s continued reliance on equity-based incentives to retain and incentivise key leadership as it advances its therapeutic pipeline.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited, which has recently adopted the Tryptamine Therapeutics branding, is an ASX-listed company operating in the biotechnology and therapeutics sector. It is focused on developing treatment options leveraging neurodynamic and related technologies, positioning itself within the emerging market for innovative neurological and mental health therapies.
Average Trading Volume: 2,536,966
Technical Sentiment Signal: Sell
Current Market Cap: A$53.11M
For an in-depth examination of ENP stock, go to TipRanks’ Overview page.